Full text is available at the source.
Abstract
Data on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in adults with Type 2 diabetes and a body mass index (BMI) below 27 kg/m² is limited.
- Most evidence for GLP-1 RAs comes from trials involving individuals who are overweight or obese.
- The effectiveness and safety of GLP-1 RAs in those with a lower BMI remain unclear.
- Research specifically targeting adults with Type 2 diabetes and lower BMI is sparse.
Simplified